Skip to main content
Erschienen in: Wiener klinische Wochenschrift 1-2/2018

12.09.2017 | original article

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy

Final results of the Austrian PegHope study

verfasst von: Prof Michael Gschwantler, MD, Hermann Laferl, MD, Prof Wolfgang Vogel, MD, Wolfgang Korak, MD, Stephan Moser, MD, Prof Harald Hofer, MD, Bernhard Bauer, MD, Michael Schleicher, MD, Barbara Bognar, MD, Martin Bischof, MD, Prof Rudolf Stauber, MD, Prof Andreas Maieron, MD, Prof Peter Ferenci, MD, Austrian Hepatitis Study Group

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2018

Einloggen, um Zugang zu erhalten

Summary

Background

Patients with a history of intravenous drug abuse included in an official opioid substitution program represent an important subgroup of patients with chronic hepatitis C. The objective of this study was to assess the efficacy of and adherence to treatment with peginterferon and ribavirin in Austrian patients on stable opioid substitution therapy (OST).

Methods

This prospective, multicenter, observational, non-interventional trial (clinicaltrials.gov identifier, NCT01416610) included treatment-naïve patients with chronic hepatitis C on OST. Treatment consisted of peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24–72 weeks, according to GT and viral response.

Results

The intention-to-treat (ITT) population comprised 88 patients. Mean duration of therapy was 6.0 ± 2.8 months. Treatment was discontinued earlier than planned in 34 out of 88 patients (39%), mainly because of poor adherence or side effects of treatment. At the end of treatment 65/88 patients (74%) were PCR negative. During follow-up, 5 patients relapsed. Only 44/88 patients (50%) could be evaluated 24 weeks after the end of treatment. Sustained virologic response 24 weeks after end of therapy (SVR24) was documented in 39/88 patients (44%). If only patients were considered who finished treatment as planned and for whom results at follow-up week 24 were available, the SVR24 rate was 89% (32/36).

Conclusion

Despite favorable prognostic factors, such as young age and a high proportion of GT3, SVR rates were low in this cohort of patients receiving OST, the main reason being poor adherence; however, in those patients completing treatment, the SVR rate was high.
Literatur
1.
Zurück zum Zitat European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–95.CrossRef European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–95.CrossRef
2.
Zurück zum Zitat Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.CrossRefPubMedPubMedCentral Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–83.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Eurosurveillance. 2011;16(48):9–13. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Eurosurveillance. 2011;16(48):9–13.
4.
Zurück zum Zitat Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31:331–9.CrossRefPubMed Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis. 2011;31:331–9.CrossRefPubMed
5.
6.
Zurück zum Zitat Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit drug-users? N Engl J Med. 2001;345:211–5.CrossRefPubMedPubMedCentral Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit drug-users? N Engl J Med. 2001;345:211–5.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat National Institutes of Health. NHI Consensus Development Conference Panel statement. Management of hepatitis C. Hepatology. 1997;26:S2–S10.CrossRef National Institutes of Health. NHI Consensus Development Conference Panel statement. Management of hepatitis C. Hepatology. 1997;26:S2–S10.CrossRef
8.
Zurück zum Zitat European Association for the Study of the Liver (EASL). Consensus statement. International Consensus Conference on Hepatitis C. J. Hepatology. 1999;30:956–61.CrossRef European Association for the Study of the Liver (EASL). Consensus statement. International Consensus Conference on Hepatitis C. J. Hepatology. 1999;30:956–61.CrossRef
10.
Zurück zum Zitat Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ. International network on hepatitis in substance users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57(Suppl. 2):S129–S37.CrossRefPubMed Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ. International network on hepatitis in substance users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57(Suppl. 2):S129–S37.CrossRefPubMed
12.
Zurück zum Zitat European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.CrossRef
13.
Zurück zum Zitat Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120–4.CrossRefPubMed Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120–4.CrossRefPubMed
14.
Zurück zum Zitat Strader DB, Wright T, Thomas DL, Seef LB, American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39:1147–71.CrossRefPubMed Strader DB, Wright T, Thomas DL, Seef LB, American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39:1147–71.CrossRefPubMed
15.
Zurück zum Zitat Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, Isler M, Broers B, Kölliker C, Schönbucher P, Frei M, Huber M. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion. 2008;78:123–30.CrossRefPubMed Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, Isler M, Broers B, Kölliker C, Schönbucher P, Frei M, Huber M. Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion. 2008;78:123–30.CrossRefPubMed
16.
Zurück zum Zitat Ebner N, Wanner C, Winkelbaur B, Matzenauer C, Aeschbach C, Thau K, Fischer G. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol. 2009;14:227–37.CrossRefPubMed Ebner N, Wanner C, Winkelbaur B, Matzenauer C, Aeschbach C, Thau K, Fischer G. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol. 2009;14:227–37.CrossRefPubMed
17.
Zurück zum Zitat Neukam K, Mira JA, Gilabert I, Claro E, Vázquez MJ, Cifuentes C, García-Rey S, Merchante N, Almeida C, Macías J, Pineda JA. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis. 2012;31:1225–32.CrossRefPubMed Neukam K, Mira JA, Gilabert I, Claro E, Vázquez MJ, Cifuentes C, García-Rey S, Merchante N, Almeida C, Macías J, Pineda JA. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. Eur J Clin Microbiol Infect Dis. 2012;31:1225–32.CrossRefPubMed
18.
Zurück zum Zitat Schulte B, Schütt S, Brack J, Isernhagen K, Deibler P, Dilg C, Verthein U, Haasen C, Reimer J. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109:248–51.CrossRefPubMed Schulte B, Schütt S, Brack J, Isernhagen K, Deibler P, Dilg C, Verthein U, Haasen C, Reimer J. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend. 2010;109:248–51.CrossRefPubMed
19.
Zurück zum Zitat Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction. 2011;106:977–84.CrossRefPubMed Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction. 2011;106:977–84.CrossRefPubMed
20.
Zurück zum Zitat Jerkeman A, Norkrans G, Lidman C, Westin J, Lagging M, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities—completion rates and efficacy. Eur J Gastroenterol Hepatol. 2014;26:523–31.CrossRefPubMed Jerkeman A, Norkrans G, Lidman C, Westin J, Lagging M, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities—completion rates and efficacy. Eur J Gastroenterol Hepatol. 2014;26:523–31.CrossRefPubMed
21.
Zurück zum Zitat Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, ETHOS Study Group.. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016;111(2):311–9.CrossRefPubMed Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, ETHOS Study Group.. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016;111(2):311–9.CrossRefPubMed
22.
Zurück zum Zitat McConachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol. 2016;9(2):287–302.CrossRefPubMed McConachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol. 2016;9(2):287–302.CrossRefPubMed
24.
Zurück zum Zitat Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P, Austrian Hepatitis Study Group. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010;138:503–12.CrossRefPubMed Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P, Austrian Hepatitis Study Group. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology. 2010;138:503–12.CrossRefPubMed
25.
Zurück zum Zitat Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–8.CrossRefPubMed Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–8.CrossRefPubMed
26.
Zurück zum Zitat Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–65.CrossRefPubMed Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–65.CrossRefPubMed
27.
Zurück zum Zitat Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.CrossRefPubMed Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.CrossRefPubMed
28.
Zurück zum Zitat Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.CrossRefPubMed Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.CrossRefPubMed
29.
Zurück zum Zitat Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K, Austrian Hepatitis Study Group.. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008;47:1816–23.CrossRefPubMed Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K, Austrian Hepatitis Study Group.. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008;47:1816–23.CrossRefPubMed
30.
Zurück zum Zitat Schütz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct observed therapy of chronic hepatitis C with an interferon-free all-oral regimen at a low-treshold drug treatment facility—a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol. 2016;111(6):903. https://doi.org/10.1038/ajg.2016.119.CrossRef Schütz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct observed therapy of chronic hepatitis C with an interferon-free all-oral regimen at a low-treshold drug treatment facility—a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol. 2016;111(6):903. https://​doi.​org/​10.​1038/​ajg.​2016.​119.CrossRef
Metadaten
Titel
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy
Final results of the Austrian PegHope study
verfasst von
Prof Michael Gschwantler, MD
Hermann Laferl, MD
Prof Wolfgang Vogel, MD
Wolfgang Korak, MD
Stephan Moser, MD
Prof Harald Hofer, MD
Bernhard Bauer, MD
Michael Schleicher, MD
Barbara Bognar, MD
Martin Bischof, MD
Prof Rudolf Stauber, MD
Prof Andreas Maieron, MD
Prof Peter Ferenci, MD
Austrian Hepatitis Study Group
Publikationsdatum
12.09.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1263-2

Weitere Artikel der Ausgabe 1-2/2018

Wiener klinische Wochenschrift 1-2/2018 Zur Ausgabe

letter to the editors

Yellow sac spiders

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.